(VBK) VERBIO Vereinigte BioEnergie - Ratings and Ratios
Exchange: XETRA •
Country: Germany •
Currency: EUR •
Type: Common Stock •
ISIN: DE000A0JL9W6
Biodiesel, Bioethanol, Biomethane, Pharmaceuticals, Fertilizers
VBK EPS (Earnings per Share)
VBK Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 59.0% |
| Value at Risk 5%th | 89.4% |
| Relative Tail Risk | -7.80% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.83 |
| Alpha | 34.09 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.382 |
| Beta | 0.328 |
| Beta Downside | 0.215 |
| Drawdowns 3y | |
|---|---|
| Max DD | 89.03% |
| Mean DD | 65.20% |
| Median DD | 73.38% |
Description: VBK VERBIO Vereinigte BioEnergie October 22, 2025
Verbio SE (XETRA:VBK) is a German-based producer of renewable fuels and bio-based chemicals, operating across Biodiesel, Bioethanol/Biomethane, and ancillary “Other” segments. Its product portfolio spans biodiesel, bioethanol, biomethane, pharma-grade glycerine, olefin metathesis catalysts, animal feeds (Verbio Proti Flow, Verbio Grain Pro), phytosterols (Sterocellent), and fertilizers, plus associated trading, transport, and logistics services. Customers range from oil refineries and pharma firms to energy utilities, fleet operators, and agricultural enterprises.
Key quantitative points (as of FY 2023) include: • Annual production capacity of roughly 1.5 Mt of biodiesel and 0.9 Mt of bioethanol, with a 12 % EBITDA margin and net-debt/EBITDA of 2.1×. • Revenue growth of 8 % YoY, driven largely by the EU’s Renewable Energy Directive (RED II) which mandates a 14 % renewable fuel blend in transport fuels by 2025, tightening demand for Verbio’s offerings. • Feedstock cost volatility-particularly the price of rapeseed oil and wheat-remains the primary earnings driver, while the company’s recent acquisition of a U.S. corn-based ethanol plant diversifies its feedstock mix and geographic exposure.
For a deeper quantitative assessment, the ValueRay platform provides a granular view of Verbio’s financials and market positioning.
VBK Stock Overview
| Market Cap in USD | 1,292m |
| Sub-Industry | Specialty Chemicals |
| IPO / Inception | |
| Return 12m vs S&P 500 | 23.3% |
| Analyst Rating | - |
VBK Dividends
| Dividend Yield | 1.16% |
| Yield on Cost 5y | 0.96% |
| Yield CAGR 5y | 18.92% |
| Payout Consistency | 97.5% |
| Payout Ratio | 64.5% |
VBK Growth Ratios
| CAGR 3y | -37.38% |
| CAGR/Max DD Calmar Ratio | -0.42 |
| CAGR/Mean DD Pain Ratio | -0.57 |
| Current Volume | 206.3k |
| Average Volume | 182.9k |
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (-119.1m TTM) > 0 and > 6% of Revenue (6% = 99.6m TTM) |
| FCFTA -0.09 (>2.0%) and ΔFCFTA -4.51pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 14.71% (prev 21.16%; Δ -6.45pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.00 (>3.0%) and CFO 2.69m > Net Income -119.1m (YES >=105%, WARN >=100%) |
| Net Debt (216.6m) to EBITDA (21.6m) ratio: 10.01 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.78 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (63.7m) change vs 12m ago -0.66% (target <= -2.0% for YES) |
| Gross Margin 6.49% (prev 16.40%; Δ -9.91pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 125.5% (prev 112.4%; Δ 13.12pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -5.70 (EBITDA TTM 21.6m / Interest Expense TTM 16.8m) >= 6 (WARN >= 3) |
Altman Z'' 1.63
| (A) 0.19 = (Total Current Assets 556.2m - Total Current Liabilities 312.1m) / Total Assets 1.28b |
| (B) 0.15 = Retained Earnings (Balance) 193.6m / Total Assets 1.28b |
| (C) -0.07 = EBIT TTM -95.8m / Avg Total Assets 1.32b |
| (D) 0.36 = Book Value of Equity 193.6m / Total Liabilities 540.2m |
| Total Rating: 1.63 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 18.77
| 1. Piotroski 3.50pt = -1.50 |
| 2. FCF Yield -8.79% = -4.39 |
| 3. FCF Margin -7.05% = -2.64 |
| 4. Debt/Equity 0.36 = 2.44 |
| 5. Debt/Ebitda 10.01 = -2.50 |
| 6. ROIC - WACC (= -16.24)% = -12.50 |
| 7. RoE -14.60% = -2.43 |
| 8. Rev. Trend -45.92% = -3.44 |
| 9. EPS Trend -85.08% = -4.25 |
What is the price of VBK shares?
As of November 15, 2025, the stock is trading at EUR 17.18 with a total of 206,300 shares traded.
Over the past week, the price has changed by +4.63%, over one month by +30.05%, over three months by +66.96% and over the past year by +41.37%.
Over the past week, the price has changed by +4.63%, over one month by +30.05%, over three months by +66.96% and over the past year by +41.37%.
Is VERBIO Vereinigte BioEnergie a good stock to buy?
No, based on ValueRay´s Fundamental Analyses, VERBIO Vereinigte BioEnergie (XETRA:VBK) is currently (November 2025)
a stock to sell. It has a ValueRay Fundamental Rating of 18.77 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of VBK is around 14.97 EUR . This means that VBK is currently overvalued and has a potential downside of -12.86%.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of VBK is around 14.97 EUR . This means that VBK is currently overvalued and has a potential downside of -12.86%.
Is VBK a buy, sell or hold?
VERBIO Vereinigte BioEnergie has no consensus analysts rating.
What are the forecasts/targets for the VBK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 14.7 | -14.7% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 16.3 | -5.2% |
VBK Fundamental Data Overview January 01, 1970
Market Cap USD = 1.29b (1.12b EUR * 1.159 EUR.USD)
Market Cap EUR = 1.12b (1.12b EUR * 1.0 EUR.EUR)
P/S = 0.7024
P/B = 1.5398
Beta = 0.745
Revenue TTM = 1.66b EUR
EBIT TTM = -95.8m EUR
EBITDA TTM = 21.6m EUR
Long Term Debt = 173.4m EUR (from longTermDebt, last quarter)
Short Term Debt = 95.4m EUR (from shortLongTermDebt, last quarter)
Debt = 268.9m EUR (from shortLongTermDebtTotal, last fiscal year)
Net Debt = 216.6m EUR (from netDebt column, last quarter)
Enterprise Value = 1.33b EUR (1.12b + Debt 268.9m - CCE 52.2m)
Interest Coverage Ratio = -5.70 (Ebit TTM -95.8m / Interest Expense TTM 16.8m)
FCF Yield = -8.79% (FCF TTM -117.0m / Enterprise Value 1.33b)
FCF Margin = -7.05% (FCF TTM -117.0m / Revenue TTM 1.66b)
Net Margin = -7.18% (Net Income TTM -119.1m / Revenue TTM 1.66b)
Gross Margin = 6.49% ((Revenue TTM 1.66b - Cost of Revenue TTM 1.55b) / Revenue TTM)
Gross Margin QoQ = 13.21% (prev -16.38%)
Tobins Q-Ratio = 1.04 (Enterprise Value 1.33b / Total Assets 1.28b)
Interest Expense / Debt = 0.91% (Interest Expense 2.44m / Debt 268.9m)
Taxrate = -122.1% (out of range, set to none) (2.22m / -1.82m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 1.78 (Total Current Assets 556.2m / Total Current Liabilities 312.1m)
Debt / Equity = 0.36 (Debt 268.9m / totalStockholderEquity, last quarter 743.2m)
Debt / EBITDA = 10.01 (Net Debt 216.6m / EBITDA 21.6m)
Debt / FCF = -1.85 (negative FCF - burning cash) (Net Debt 216.6m / FCF TTM -117.0m)
Total Stockholder Equity = 815.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -9.28% (Net Income -119.1m / Total Assets 1.28b)
RoE = -14.60% (Net Income TTM -119.1m / Total Stockholder Equity 815.7m)
RoCE = -9.69% (EBIT -95.8m / Capital Employed (Equity 815.7m + L.T.Debt 173.4m))
RoIC = -10.42% (negative operating profit) (EBIT -95.8m / (Assets 1.28b - Curr.Liab 312.1m - Cash 52.2m))
WACC = 5.82% (E(1.12b)/V(1.38b) * Re(7.22%) + (debt cost/tax rate unavailable))
Discount Rate = 7.22% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -10.98%
Fair Price DCF = unknown (Cash Flow -117.0m)
EPS Correlation: -85.08 | EPS CAGR: -81.18% | SUE: -2.27 | # QB: 0
Revenue Correlation: -45.92 | Revenue CAGR: -3.66% | SUE: 1.76 | # QB: 1
Market Cap EUR = 1.12b (1.12b EUR * 1.0 EUR.EUR)
P/S = 0.7024
P/B = 1.5398
Beta = 0.745
Revenue TTM = 1.66b EUR
EBIT TTM = -95.8m EUR
EBITDA TTM = 21.6m EUR
Long Term Debt = 173.4m EUR (from longTermDebt, last quarter)
Short Term Debt = 95.4m EUR (from shortLongTermDebt, last quarter)
Debt = 268.9m EUR (from shortLongTermDebtTotal, last fiscal year)
Net Debt = 216.6m EUR (from netDebt column, last quarter)
Enterprise Value = 1.33b EUR (1.12b + Debt 268.9m - CCE 52.2m)
Interest Coverage Ratio = -5.70 (Ebit TTM -95.8m / Interest Expense TTM 16.8m)
FCF Yield = -8.79% (FCF TTM -117.0m / Enterprise Value 1.33b)
FCF Margin = -7.05% (FCF TTM -117.0m / Revenue TTM 1.66b)
Net Margin = -7.18% (Net Income TTM -119.1m / Revenue TTM 1.66b)
Gross Margin = 6.49% ((Revenue TTM 1.66b - Cost of Revenue TTM 1.55b) / Revenue TTM)
Gross Margin QoQ = 13.21% (prev -16.38%)
Tobins Q-Ratio = 1.04 (Enterprise Value 1.33b / Total Assets 1.28b)
Interest Expense / Debt = 0.91% (Interest Expense 2.44m / Debt 268.9m)
Taxrate = -122.1% (out of range, set to none) (2.22m / -1.82m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 1.78 (Total Current Assets 556.2m / Total Current Liabilities 312.1m)
Debt / Equity = 0.36 (Debt 268.9m / totalStockholderEquity, last quarter 743.2m)
Debt / EBITDA = 10.01 (Net Debt 216.6m / EBITDA 21.6m)
Debt / FCF = -1.85 (negative FCF - burning cash) (Net Debt 216.6m / FCF TTM -117.0m)
Total Stockholder Equity = 815.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -9.28% (Net Income -119.1m / Total Assets 1.28b)
RoE = -14.60% (Net Income TTM -119.1m / Total Stockholder Equity 815.7m)
RoCE = -9.69% (EBIT -95.8m / Capital Employed (Equity 815.7m + L.T.Debt 173.4m))
RoIC = -10.42% (negative operating profit) (EBIT -95.8m / (Assets 1.28b - Curr.Liab 312.1m - Cash 52.2m))
WACC = 5.82% (E(1.12b)/V(1.38b) * Re(7.22%) + (debt cost/tax rate unavailable))
Discount Rate = 7.22% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -10.98%
Fair Price DCF = unknown (Cash Flow -117.0m)
EPS Correlation: -85.08 | EPS CAGR: -81.18% | SUE: -2.27 | # QB: 0
Revenue Correlation: -45.92 | Revenue CAGR: -3.66% | SUE: 1.76 | # QB: 1